The new paradigm of systemic therapies for metastatic melanoma

Publication date: August 2017
Source:Journal of the American Academy of Dermatology, Volume 77, Issue 2
Author(s): Virginia O. Volpe, Daniel M. Klufas, Upendra Hegde, Jane M. Grant-Kels
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.



http://ift.tt/2tMR2fP